Want to see SEPN full AI Analyst Report?
Top Page
Septerna, Inc.
(NASDAQ:SEPN)
Select Model
Select Model
Rating:62Neutral
Price Target:
$39.00
▼(-5.57% Downside)
Action:Reiterated
Date:08/25/26
The score is primarily supported by improving financial trajectory (rapid revenue scaling and strong recent operating/free cash flow) and an upward technical trend (price above major moving averages with positive MACD). These positives are tempered by continued net losses and a weak conventional valuation profile (negative P/E with no dividend yield), while recent corporate events are constructive but secondary.
Positive Factors
Rapid revenue scaling
Revenue has more than doubled from 2025 while maintaining healthy gross profitability, indicating meaningful commercial or partnership traction. If this scale is sustained, it can provide a stronger base for funding research, supporting development programs, and eventually absorbing operating costs.
Negative Factors
Persistent net losses
Septerna has not yet converted its revenue growth and gross profitability into overall earnings, because operating costs continue to exceed revenue. Continued net losses can consume resources and require sustained financial support until development spending produces durable commercial returns.
Read all positive and negative factors
Positive Factors
Negative Factors
Rapid revenue scaling
Revenue has more than doubled from 2025 while maintaining healthy gross profitability, indicating meaningful commercial or partnership traction. If this scale is sustained, it can provide a stronger base for funding research, supporting development programs, and eventually absorbing operating costs.
Read all positive factors
Septerna, Inc. (SEPN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.76B
Dividend YieldN/A
Average Volume (3M)337.50K
Price to Earnings (P/E)―
Beta (1Y)2.09
Revenue Growth13520.11%
EPS Growth74.95%
CountryUS
Employees123
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.54
Shares Outstanding46,676,950
10 Day Avg. Volume344,248
30 Day Avg. Volume337,505
Financial Highlights & Ratios
PEG Ratio0.59
Price to Book (P/B)3.23
Price to Sales (P/S)26.85
P/FCF Ratio11.25
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$52.88Price Target Upside28.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-1.32
Revenue Forecast (FY)$97.64M
Septerna, Inc. Business Overview & Revenue Model
Company Description
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1...
Septerna, Inc. Financial Statement Overview
Summary
Income Statement
48
Neutral
Balance Sheet
72
Positive
Cash Flow
78
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 98.88M | 45.95M | 1.07M | 151.00K | 0.00 |
| Gross Profit | 98.46M | 45.95M | 1.07M | 151.00K | 0.00 |
| EBITDA | -39.75M | -47.26M | -70.89M | -44.70M | -27.39M |
| Net Income | -24.24M | -48.88M | -71.80M | 4.18M | -27.68M |
Balance Sheet | |||||
| Total Assets | 566.74M | 596.19M | 456.55M | 130.87M | 36.12M |
| Cash, Cash Equivalents and Short-Term Investments | 372.32M | 391.09M | 350.92M | 88.48M | 30.61M |
| Total Debt | 22.55M | 23.63M | 25.48M | 12.57M | 710.00K |
| Total Liabilities | 180.02M | 214.26M | 36.51M | 169.24M | 80.32M |
| Stockholders Equity | 386.72M | 381.93M | 420.05M | -38.37M | -44.20M |
Cash Flow | |||||
| Free Cash Flow | 105.10M | 109.67M | -69.57M | -41.60M | -24.59M |
| Operating Cash Flow | 106.01M | 110.19M | -67.47M | -38.72M | -23.30M |
| Investing Cash Flow | -229.10M | -229.35M | -160.60M | 22.12M | -1.29M |
| Financing Cash Flow | 18.44M | 1.69M | 377.78M | 74.52M | 30.05M |
Septerna, Inc. Technical Analysis
Neutral
41.30
Price Trends
38.54
Negative
34.99
Positive
30.56
Positive
Market Momentum
-0.14
Positive
45.65
Neutral
27.66
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SEPN, the sentiment is Neutral. The current price of 41.3 is above the 20-day moving average (MA) of 38.28, above the 50-day MA of 38.54, and above the 200-day MA of 30.56, indicating a neutral trend. The MACD of -0.14 indicates Positive momentum. The RSI at 45.65 is Neutral, neither overbought nor oversold. The STOCH value of 27.66 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SEPN.
Septerna, Inc. Risk Analysis
Septerna, Inc. disclosed 89 risk factors in its most recent earnings report. Septerna, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
We expect to lose our smaller reporting company status, which will increase our reporting and compliance obligations. Q2, 2026
Septerna, Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | $884.18M | 16.01 | 19.40% | ― | 35.11% | 331.61% | |
62 Neutral | $1.76B | -69.94 | -6.31% | ― | 13520.11% | 74.95% | |
62 Neutral | $1.97B | -14.19 | -35.42% | ― | -3.28% | 61.09% | |
58 Neutral | $957.22M | -3.19 | -207.18% | ― | -7.27% | -48.89% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
44 Neutral | $66.85M | -0.24 | 108.75% | ― | 32.43% | 7.41% |
* General Sector Average
SEPN
Septerna, Inc.
37.77
19.62
108.10%
TBPH
Theravance Biopharma
17.03
2.60
18.02%
KURA
Kura Oncology
10.76
1.79
19.96%
GOSS
Gossamer Bio
10.94
-214.66
-95.15%
MRVI
Maravai Lifesciences Holdings
7.60
4.77
168.55%
Septerna, Inc. Corporate Events
Business Operations and StrategyExecutive/Board Changes
Septerna Appoints Rajiv Patni as Chief Medical Officer
Positive
Aug 25, 2026
Septerna, Inc., a clinical-stage biotechnology company specializing in GPCR-targeted oral small-molecule therapies for unmet needs in endocrinology, immunology, inflammation and metabolic diseases, is building a diversified pipeline enabled by its...
Executive/Board ChangesShareholder Meetings
Septerna Shareholders Elect Directors, Ratify Ernst & Young
Positive
Jun 30, 2026
At its annual meeting of stockholders held on June 26, 2026, Septerna, Inc. reported that shareholders elected Shalini Sharp and Jake Simson as Class II directors to the Board for three‑year terms ending in 2029, with both to serve until suc...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.